Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase

Ehab Atallah, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: Imatinib mesylate, a tyrosine kinase inhibitor, has revolutionized the therapy of newly diagnosed patients with chronic myeloid leukemia. Prior to imatinib, treatment algorithms for chronic myeloid leukemia patients recommended stem cell transplantation for patients less than 50 years old who had a donor and could undergo stem cell transplantation. Other than stem cell transplantation, interferon was the only drug that could induce cytogenetic remissions in minority of patients. RECENT FINDINGS: After 5 years of follow-up, the rate of relapse with imatinib therapy continues to decrease, and the numbers of patients achieving a complete molecular response continue to increase. In addition, with a longer follow up, imatinib continues to be safe and easily tolerated. Recent studies have shown a survival benefit with imatinib. The use of imatinib before stem cell transplant did not have an effect on mortality or morbidity posttransplant. SUMMARY: Currently, imatinib is considered first line therapy in all patients with early chronic phase chronic myeloid leukemia with stem cell transplant reserved for patients who have disease resistant to imatinib therapy. Our aim is to review current recommendations for initial therapy of patients with early chronic phasechronic myeloid leukemia, current areas of controversy and future directions.

Original languageEnglish (US)
Pages (from-to)138-144
Number of pages7
JournalCurrent Opinion in Hematology
Volume14
Issue number2
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Stem Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Stem Cells
Transplants
Imatinib Mesylate
Cytogenetics
Protein-Tyrosine Kinases
Interferons
Tissue Donors
Morbidity
Recurrence
Survival
Mortality

Keywords

  • Chronic myeloid leukemia
  • Imatinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. / Atallah, Ehab; Cortes, Jorge.

In: Current Opinion in Hematology, Vol. 14, No. 2, 01.03.2007, p. 138-144.

Research output: Contribution to journalReview article

@article{d8a976d17a074614b832bdc8e0457379,
title = "Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase",
abstract = "PURPOSE OF REVIEW: Imatinib mesylate, a tyrosine kinase inhibitor, has revolutionized the therapy of newly diagnosed patients with chronic myeloid leukemia. Prior to imatinib, treatment algorithms for chronic myeloid leukemia patients recommended stem cell transplantation for patients less than 50 years old who had a donor and could undergo stem cell transplantation. Other than stem cell transplantation, interferon was the only drug that could induce cytogenetic remissions in minority of patients. RECENT FINDINGS: After 5 years of follow-up, the rate of relapse with imatinib therapy continues to decrease, and the numbers of patients achieving a complete molecular response continue to increase. In addition, with a longer follow up, imatinib continues to be safe and easily tolerated. Recent studies have shown a survival benefit with imatinib. The use of imatinib before stem cell transplant did not have an effect on mortality or morbidity posttransplant. SUMMARY: Currently, imatinib is considered first line therapy in all patients with early chronic phase chronic myeloid leukemia with stem cell transplant reserved for patients who have disease resistant to imatinib therapy. Our aim is to review current recommendations for initial therapy of patients with early chronic phasechronic myeloid leukemia, current areas of controversy and future directions.",
keywords = "Chronic myeloid leukemia, Imatinib, Tyrosine kinase inhibitors",
author = "Ehab Atallah and Jorge Cortes",
year = "2007",
month = "3",
day = "1",
doi = "10.1097/MOH.0b013e32801684a3",
language = "English (US)",
volume = "14",
pages = "138--144",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase

AU - Atallah, Ehab

AU - Cortes, Jorge

PY - 2007/3/1

Y1 - 2007/3/1

N2 - PURPOSE OF REVIEW: Imatinib mesylate, a tyrosine kinase inhibitor, has revolutionized the therapy of newly diagnosed patients with chronic myeloid leukemia. Prior to imatinib, treatment algorithms for chronic myeloid leukemia patients recommended stem cell transplantation for patients less than 50 years old who had a donor and could undergo stem cell transplantation. Other than stem cell transplantation, interferon was the only drug that could induce cytogenetic remissions in minority of patients. RECENT FINDINGS: After 5 years of follow-up, the rate of relapse with imatinib therapy continues to decrease, and the numbers of patients achieving a complete molecular response continue to increase. In addition, with a longer follow up, imatinib continues to be safe and easily tolerated. Recent studies have shown a survival benefit with imatinib. The use of imatinib before stem cell transplant did not have an effect on mortality or morbidity posttransplant. SUMMARY: Currently, imatinib is considered first line therapy in all patients with early chronic phase chronic myeloid leukemia with stem cell transplant reserved for patients who have disease resistant to imatinib therapy. Our aim is to review current recommendations for initial therapy of patients with early chronic phasechronic myeloid leukemia, current areas of controversy and future directions.

AB - PURPOSE OF REVIEW: Imatinib mesylate, a tyrosine kinase inhibitor, has revolutionized the therapy of newly diagnosed patients with chronic myeloid leukemia. Prior to imatinib, treatment algorithms for chronic myeloid leukemia patients recommended stem cell transplantation for patients less than 50 years old who had a donor and could undergo stem cell transplantation. Other than stem cell transplantation, interferon was the only drug that could induce cytogenetic remissions in minority of patients. RECENT FINDINGS: After 5 years of follow-up, the rate of relapse with imatinib therapy continues to decrease, and the numbers of patients achieving a complete molecular response continue to increase. In addition, with a longer follow up, imatinib continues to be safe and easily tolerated. Recent studies have shown a survival benefit with imatinib. The use of imatinib before stem cell transplant did not have an effect on mortality or morbidity posttransplant. SUMMARY: Currently, imatinib is considered first line therapy in all patients with early chronic phase chronic myeloid leukemia with stem cell transplant reserved for patients who have disease resistant to imatinib therapy. Our aim is to review current recommendations for initial therapy of patients with early chronic phasechronic myeloid leukemia, current areas of controversy and future directions.

KW - Chronic myeloid leukemia

KW - Imatinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33846591021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846591021&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e32801684a3

DO - 10.1097/MOH.0b013e32801684a3

M3 - Review article

C2 - 17255791

AN - SCOPUS:33846591021

VL - 14

SP - 138

EP - 144

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -